AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03489005 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: BIA 5-1058
Description: Subjects will receive BIA 5-1058 tablets (containing 100 mg) as single, oral doses 30 minutes after the start of a moderate mealas follows:~* 400 mg BIA 5 1058, as 4 × 100 mg tablets and 8 placebo tablets~* 1200 mg BIA 5 1058, as 12 × 100 mg tablets
Study NCT03489005 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo Oral Tablet
Description: Matching placebo tablets administered as follows:~- placebo, as 12 × 0-mg tablets
Study NCT03489005 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Moxifloxacin 400 mg
Description: Administered as follows:~- 400 mg moxifloxacin, as 1 × 400-mg tablet
Study NCT01015222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Starting dose of 50 mg daily PO for 28 day cycle
Study NCT01015222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Starting dose 5 mg/kg IV Day 1 and 15
Study NCT01015222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Starting dose 40 mg/m2 IV Day 1, 8 and 15
Study NCT03432949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone plus Radium-223
Description: Dexamethasone will be administered as 0.5 mg capsules by mouth per day during the duration of the Radium-223 treatment.
Study NCT01424059 — intervention group
Intervention type: OTHER
Intervention: WEDQ-B (questionnaire)
Description: Questionnaires are answered after delivery; within 48 hours and after five weeks
Study NCT01987830 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: MRI-PET
Description: * \[11C\] temozolomide for PET scan and a contrast dye for the MRI scan~* Drawing blood to assess the radioactivity of \[11C\] temozolomide
Study NCT01987830 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: TMZ-PET
Description: The PET scan will take approximately 90 minutes. You will receive one injection of \[11C\] temozolomide. Following the injection of the radioactive substance, blood samples will be taken from the second IV line.
Study NCT02337712 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: q.d. RT
Description: 65 Gy in 26 fractions
Study NCT02337712 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: b.i.d.RT
Description: 45 Gy in 30 fractions
Study NCT02337712 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etoposide and cisplatin
Description: etoposide and cisplatin concurrent with radiotherapy
Study NCT02337712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide and cisplatin
Description: etoposide and cisplatin concurrent with radiotherapy
Study NCT03770013 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine
Description: bupivacaine 0.25% a total volume of 40 ml (20 ml each side
Study NCT03770013 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: bupivacaine
Description: bupivacaine 0.25% a total volume of 40 ml (20 ml each side
Study NCT03770013 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine 0.5 mcg/kg
Study NCT03770013 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clonidine
Description: 1ug/kg clonidine
Study NCT04047134 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Action Observation Treatrment
Description: Participants will be asked to carefully observe the videos showing different daily actions. Each action will consist of 3 to 4 constituent motor acts. Each motor act will be presented for 3 minutes, totally lasting 12 min/video. At the end of each motor act presentation, participants will be asked to execute with the affected hand the observed motor sequence for 2 minutes (20 minutes/session). 10 daily actions will be recorded. Each video will be presented to participants twice a day, in order to complexity as judged by the experimenter. Only 1 typology of motor task per day for each condition, starting from the easiest and ending with the most complex action throughout 15 sessions spread on 5 weeks (3 sessions/week). Tasks will be based on some relevant activities of daily living belonging to at least one between feeding, self-care or external actions category on the affected side. Each session will last about 15 minutes and will be repeated twice a day, at least 60 minutes apart.
Study NCT04047134 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Observation of videos with Non Motor contents
Description: Participants will be asked to observe video clips with no specific motor content. Videos will concern scientific, geographical and historical issues. As for cases, video clips will be divided into three to four parts. At the end of each part, controls will execute the same actions as cases, in the same order. In this way cases and controls will undergo the same amount of motor practice and receive the same amount of visual stimulation, the only difference being the content of visual stimuli.
Study NCT03366324 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Second generation CAR-T cells
Description: Patients receive CD19 CAR-T cells transduced with a lentiviral vector on days 0, 1, and 2.
Study NCT03366324 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hematological stem cell transplantation
Description: Patients receive hematological stem cell transplantations within 3 months after they achieve MRD- remissions after CAR-T therapies.
Study NCT03211923 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Transcranial magnetic stimulation (TMS)
Description: Single pulse, monophasic transcranial magnetic stimulation
Study NCT02662400 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MNCs
Description: 200 - 300 ml of bone marrow will be aspirated and layered on density gradient medium (Ficoll - hypaque ) and stem cells will be separated. Separated mono nucleated cells will injected into superior pancreatico duodenal artery. Patients will be urged to monitor and document blood glucose readings for next 6 months. Glucagon stimulated C - peptide HYPERGLYCEMIC CLAMP FOR ASSESSMENT OF BETA CELL FUNCTION , AND EUGLYCEMIC CLAMP TO ASSESS INSULIN SENSITIVITY .Homeostasis Model of Assessment - Insulin Resistance and Beta cell function ,HbA1c, lipid profile and biochemistry will be done at baseline and 6 months
Study NCT01953835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2586184 standard formulation
Description: GSK2586184 standard formulation is a white film coated round biconvex 200 mg oral tablet. For cohort A, it is to be administered at 400 mg (200 mg x 2 tablets) twice daily from Day 6 to Day 14. For cohort B, it is to be administered at 400 mg (200 mg x 2 tablets) single dose after standard breakfast either on Day 1, 4 and 7 according to the treatment sequence, each separated by a 3-day wash out period.
Study NCT01953835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Simvastatin 10 mg oral tablet is peach-coloured, oval-shaped tablets. It is to be administered orally as a single dose of 10 mg tablet on the mornings of Day 1 and Day 10.
Study NCT01953835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: GSK2586184 new formulation without poloxamer is a white film coated round biconvex 200 mg oral tablet. In cohort B, it is to be administered at 400 mg (200 mg x 2 tablets) single dose once after standard breakfast and once after overnight fasting, either on Day 1, 4 and 7 according to the treatment sequence, each separated by a 3-day washout period.
Study NCT01953835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2586184 new formulation
Description: GSK2586184 new formulation without poloxamer is a white film coated round biconvex 200 mg oral tablet. In cohort B, it is to be administered at 400 mg (200 mg x 2 tablets) single dose once after standard breakfast and once after overnight fasting, either on Day 1, 4 and 7 according to the treatment sequence, each separated by a 3-day washout period.
Study NCT03714646 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: beta glucan and resistant starch
Description: 12g per day the day before the CID Resistant starch 7.5 g
Study NCT03714646 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: isocaloric maltodextrin before the CID
Study NCT03714646 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: beta gluten
Description: 12 g beta gluten there day before the CID
Study NCT02255318 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Taurolock
Study NCT02255318 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00897962 — intervention group
Intervention type: OTHER
Intervention: Healthy Controls
Description: One blood draw (2 teaspoons)
Study NCT00897962 — intervention group
Intervention type: OTHER
Intervention: Metastatic Breast Cancer
Description: Blood samples will be drawn every 3 months, for up to 18 months.
Study NCT00897962 — intervention group
Intervention type: OTHER
Intervention: Non-cancer medical illness
Description: One blood draw (2 teaspoons)
Study NCT01899716 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Study NCT02202044 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intravesical BCG and EMDA/MMC
Description: Patients are assigned one course of treatment per week for 6 weeks with sequential 'Intravesical instillation of sequential Bacillus Calmette-Guérin (BCG) and Electromotive Drug Administration /Mitomycin-C
Study NCT00549913 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NeoFuse
Description: immunoselected, culture-expanded, nucleated, allogeneic MPCs (NeoFuse) combined with MasterGraft Resorbable Ceramic Granules in subjects requiring posterior lumbar interbody fusion with NuVasive's radiolucent PEEK OPTIMA cage
Study NCT00549913 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: posterolateral spinal fusion with instrumentation
Description: autograft in subjects requiring posterior lumbar interbody fusion with NuVasive's radiolucent PEEK OPTIMA cage
Study NCT03707119 — intervention group
Intervention type: OTHER
Intervention: Educational programme
Description: the health professional students were undergone to Student 4 Best Evidence blog, as a specific educational programme to learn EBP competencies.
Study NCT00437827 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Star*D algorithm
Description: Standard of care based upon the therapies selected in the Star\*D study.
Study NCT00437827 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rEEG-guided therapy
Description: An rEEG report is based upon a process that utilizes a patient's drug-free QEEG to predict successful treatment strategies.
Study NCT00655681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pamidronate
Description: The pamidronate is mixed 1 to 10 (10 cc of saline for each 1 mg pamidronate), with a minimum volume of 50 cc saline. The medication is administered as an IV infusion to run at a rate beginning at 20 cc/hr, adjusting the rate so that the infusion will run over 4 hours. For children \< 8 kg (80cc infusion), the rate would be 20 cc/hr and the duration would be determined by the volume.
Study NCT00655681 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: receives saline 10cc/kg over 4 hours post operatively in addition to routine post operative fluids
Study NCT01168310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate/Formoterol Fumarate
Description: Inhalation Suspension
Study NCT01168310 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol Fumarate
Description: Inhalation Solution
Study NCT01168310 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhalation Solution
Study NCT03101722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTHE and Huperzine A
Description: huperzine A intervention
Study NCT03101722 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: BTHE and Huperzine A
Description: huperzine A intervention
Study NCT03101722 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BETH
Description: basic treatment and health education
Study NCT03101722 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: BETH
Description: basic treatment and health education
Study NCT00900757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron (PALO)
Description: Eligible patients should receive a planned total dose of 54-60 GY of radiation and 75 mg/m2 of daily temozolomide for a total of six weeks of treatment. For each week of radiation patients will receive a single 0.25 mg intravenous dose of palonosetron 30 minutes before each week of radiation fraction. This schedule will be repeated for each week of radiation for a total of 6 weeks.
Study NCT02142361 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: enfilcon A
Description: Silicone hydrogel toric lenses.
Study NCT01004406 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intensive LDL-lowering therapy
Description: The intensive LDL-lowering therapy uses LDL-apheresis in addition to the standard statin therapy. The device used in this study is the LIPOSORBER LA-15 System, manufactured by Kaneka Pharma America LLC. A filter separates plasma from whole blood, the Liposorber -columns remove LDL from the plasma. The system recombines plasma and blood cells and returns them into the patient's body. This procedure typically takes about 3 hours. The procedure provides an immediate reduction in a patient's lipid levels. A single apheresis treatment can lower LDL by more than 80%, but levels return to baseline within 3 weeks
Study NCT01004406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard statin monotherapy
Description: The standard statin therapy of 40-80mg oral daily dose of Atorvastatin or other equivalent types of statin to lower LDL in blood for both randomized groups.
Study NCT01004406 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard statin monotherapy
Description: The standard statin therapy of 40-80mg oral daily dose of Atorvastatin or other equivalent types of statin to lower LDL in blood for both randomized groups.
Study NCT00787098 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ETM protocol
Description: ETM is 4 levels. Level 1, each receives repositioning from lateral to supine positions at even hours, totaling 60 minutes of activity/positioning over 24 hours. If tolerated, two periods of 20 minutes of supine position with a reverse trendelenberg position of 15-20 degrees will be used to promote orthostasis. Level 2 is turning every 2 hours, positioning in reverse trendelenberg at 15-25 degrees as tolerated, active resistance with ICU staff for 20 minutes daily for a total of 60-80 minutes of activity/positioning daily. At Level 3, 2 times 20 minutes of a sitting are added to active ROM and inbed turning (estimated 80-100 total minutes of activity daily). Sitting is in bed or with non-weightbearing assisted transfer to chair with backrest elevation at 75-90 degrees and legs in a dependent position. Level 3 interventions; minimal weight-bearing. Level 4, weight-bearing transfer to chair and ambulation are added to inbed turning.
Study NCT03770416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO
Study NCT03770416 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT00643461 — intervention group
Intervention type: DEVICE
Intervention: Adhesive A
Description: Applied per manufacturer's instructions.
Study NCT00643461 — intervention group
Intervention type: DEVICE
Intervention: Adhesive B
Description: Applied per manufacturer's instructions.
Study NCT00643461 — intervention group
Intervention type: DEVICE
Intervention: Adhesive C
Description: Applied per manufacturer's instructions.
Study NCT01088243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesalamine
Description: Mesalamine (5-ASA) 500 mg capsules four times per day for 6 weeks in Chronic Beryllium Disease subjects.
Study NCT01088243 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill 500 mg capsules four times per day for 6 weeks in Chronic Beryllium Disease subjects.
Study NCT03250091 — intervention group
Intervention type: PROCEDURE
Intervention: Upper endoscopy with biopsies
Description: Upper endoscopy with proper biopsy work-up will be used for identification and stratification of gastric lesions as well as acquisition of biopsies for histopathological examination, including H.pylori detection
Study NCT03250091 — intervention group
Intervention type: PROCEDURE
Intervention: Plasma/serum sampling
Description: Plasma/serum sampling will be used to obtain information for group stratification, e.g. H.pylori status determination, serum biomarkers
Study NCT03250091 — intervention group
Intervention type: PROCEDURE
Intervention: Biopsies for gastric microbiota
Description: During upper endoscopy biopsies for gastric microbiota analysis will be obtained
Study NCT03250091 — intervention group
Intervention type: PROCEDURE
Intervention: Faecal sample acquisition
Description: Faecal samples will be obtained for faecal occult blood testing as well as microbiota analysis
Study NCT03867149 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: neuroimaging
Description: neuroimaging including high-resolution imaging of the thalamus, DTI and resting state fMRI
Study NCT03770013 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: add placebo 9normal saline)
Study NCT02947464 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard clinical practice
Description: Control weight will be started in obese children to decrease upper airway resistance and airway collapsibility. Close follow-up in order to detect comorbidities.
Study NCT02947464 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard clinical practice + Rapid Maxillary Expansion
Description: Mid-palatal suture osteogenic distraction delivered through a self-activated acrylic intraoral device custom-fit into the children´s palate and maxillary posterior teeth providing a transverse expansion of the dentofacial skeleton.
Study NCT01163903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pantoprazole sodium for injection
Description: Single 3-weekly doses of pantoprazole using the following dose escalation scheme for successive groups of patients: 80, 160, 240 and 320mg i.v. of pantoprazole to be given every 3 weeks, 30-60 (±5) minutes prior to doxorubicin. Treatment will be repeated on Day 1 of a 21-day cycle until radiographic or symptomatic progression or unacceptable toxicity or a maximum of 4 cycles (for patients who have received prior anthracyclines), and up to 8 cycles (for those with no prior exposure to anthracyclines).
Study NCT01163903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride injection
Description: 60 mg/m2, IV, scheduled on day 1 of every 3-week interval, 30-60 (±5) minutes after pantoprazole administration.
Study NCT01862458 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: tPA alone
Study NCT01862458 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tPA plus dornase
Study NCT03867149 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Neuropsychological assessment
Description: neuropsychological assessment of memory, language, executive functions and mood
Study NCT04325698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06439535 (CN)
Description: 15 mg/kg, IV on day 1 of each 21 day cycle for up to 2 years, or until progression or unacceptable toxicity develops.
Study NCT04325698 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab-EU
Description: 15 mg/kg, IV on day 1 of each 21 day cycle until disease progression, unacceptable toxicity or 25 weeks. At Week 25, the participants with clinical benefit will received PF-06439535 (CN) monotherapy for up to 2 years from randomization in this study
Study NCT04325698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175 mg/m2 via IV infusions on Day 1 of a 21-day cycle for each of at least 4 and no more than six (6) 21-day cycles.
Study NCT04325698 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 175 mg/m2 via IV infusions on Day 1 of a 21-day cycle for each of at least 4 and no more than six (6) 21-day cycles.
Study NCT04325698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 5 (max=750mg) via IV infusions on Day 1 of a 21-day cycle for each of at least 4 and no more than six (6) 21-day cycles.
Study NCT04325698 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: AUC 5 (max=750mg) via IV infusions on Day 1 of a 21-day cycle for each of at least 4 and no more than six (6) 21-day cycles.
Study NCT03764358 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Arteriovenous Fistula
Description: Surgical implantation of an arteriovenous fistula for hemodialysis
Study NCT03764358 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tunneled Cuffed Catheter
Description: Placement of a tunneled cuffed catheter in surgical theatre
Study NCT01556074 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga treatment
Description: Biweekly 90-minute group yoga classes for 8 weeks and on non-class days participants will be asked to devote 15 minutes per day to a prescribed home yoga practice.
Study NCT02391935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RCS-01
Description: Cultured, autologous hair follicle cells suspended in cryomedium
Study NCT02391935 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Cryomedium